 |
|
 |
1st
EMBL/EMBO Joint Conference 2000 |
|
|
Abstracts |
|
|
| Developing new dialogue |
|
|
|
Antibiotics for the 21st century
Julian Davies, University of British Colombia, Canada
Biotechnology at the beginning of the third millennium: facts and global trends
Manfred Kern, Aventis, Germany
Biotechnology, bio-industry, bio-business
Charles Kurland, BMC, Sweden and Chris Leaver,
Oxford University, UK
Business with biotech: Europe vs. USA – reality vs. wishful thinking
Friedrich von Bohlen, lion Bioscience AG, Germany
Debating human identity: institutional commitments and consequences
Sheila Jasanoff, Harvard University, USA
Defending animal use in biotechnology
Alan Colman, PPL Therapeutics
Framing public perceptions of risk: agricultural GMOs in Europe
Claire Marris, University of Versailles, France
From Science to Society
Chair Lewis Wolpert, Professor of Biology as Applied to Medicine, University College London, UK
From Pan to pandemic: HIV and AIDS
Robin Weiss, University College London, UK
From the sequence of our genes to medical utility
Andrea Ballabio, TIGEM, Italy
Genetic research and common diseases
Karl Stefánsson, deCode Genetics, Iceland
The genomic turn: is the genome the new name of the soul?
Alexandre Mauron, University of Geneva
Medical uses of genetic information: gene therapy, prenatal diagnostics, and population genetics
Chair Jens Reich, Max-delbrck-Centrum, Germany
On human genome projects: uses and abuses
John Collinge, Imperial College London, UK
Panel discussion: biotechnology and its discontents
Julian Kinderlerer [Chair], Sheffield University,
UK
Hans-Jörg Rheinberger, MPI History of Science,
Germany
Mark Cantley, European Commission, Belgium
Sheila jasanoff, Harvard University, USA
Stefan
Flothmann, Greenpeace, Germany
David Dickinson,
Nature, UK
Panel discussion: how to restore public trust in science
Maynard Olson [Chair], University of Washington,
USA
Beate Weber, Lady Major of Heidelberg, Germany
Tom Wilkie, Wellcome Trust, UK
Julian Kinderlerer, Sheffield University, UK
Orla Smith, Science,
USA
Maurizio Laccarino, International Institute
of Genetics and Biophysics, Italy
Panel discussion:
public understanding of genetic information
Alastair Kent [Chair], Genetic Interest Group,
UK
Barbara Cohen, Ludwig Institute of Cancer Research,
USA
Jean Louis Mandel, IGBMC, France
Alexandre
Mauron, University of Geneva, Switzerland
Vivienne Parry, BBC, UK
Panel discussion: science in the spotlight
Julian Kinderlerer [Chair], Sheffield University,
UK
Past and future of behavioural genetics
Benno Müller-Hill, University of Cologne, Germany
Science in theater
Carl Djerassi, Stanford University, USA
Science in theater: an historical account
Ivo Schneider, Bunderswehr Universität, MÐnich,
Germany
The human genome project: a scientist's view of what went right and what went wrong
Maynard Olson, University of Washington, USA
The Saga of BSE
John Collinge, Imperial College, London, UK
The social costs of better disease treatments
Peter Goodfellow, SmithKleine Beecham Pharmaceuticals, UK
Why framing processes in risk science are important í but still neglected
Brian Wynne, Lancaster University, UK |
|
|
|
